EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15736989.
- Also identified by PMC identifier 549608.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Lung Neoplasms